Mylan (MYL) and Pfizer's (PFE) Upjohn to Combine
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/16/2026
- Wall Street futures subdued as focus shifts to Fed, SpaceX jumps for third day
- Fox to acquire Roku for $22 billion to create streaming and live content giant
- SpaceX extends gains premarket after biggest IPO ever values it at $2.1 trillion
- These 2 space stocks were upgraded at KeyBanc today
- Nvidia plans to raise at least $20 billion in bond sale
- Brixmor Property Group announces passing of former CEO James Taylor
- Wall Street rallies, Dow ends with record on US-Iran deal, oil price slide
- Wolfe Research sees substantial upside to AMD estimates
- This chip stock is seen as a key winner from SPCX "gravitational pull" effect
- SpaceX to acquire Cursor in $60 billion all-stock deal
UPDATE: Pfizer (PFE) Tops Q2 EPS by 5c, Revenues Miss; Lowers FY19 EPS/Revenue Guidance
July 29, 2019 6:51 AM EDT(Updated - July 29, 2019 6:54 AM EDT)
Pfizer (NYSE: PFE) reported Q2 EPS of $0.80, $0.05 better than the analyst estimate of $0.75. Revenue for the quarter came in at $13.26 billion versus the consensus estimate of $13.4 billion.
Second-Quarter 2019 Revenues of $13.3 Billion, Reflecting 2% Operational Growth Driven by 6% Operational Growth from Pfizer Biopharmaceuticals GroupSecond-Quarter 2019 Reported Diluted EPS(1) of $0.89, Adjusted Diluted EPS(2) of $0.80Updated 2019 Financial Guidance Primarily to Reflect the Anticipated August 1, 2019 Formation of the Consumer Healthcare Joint Venture with GlaxoSmithKline plc(3) and the Anticipated Near-Term Completion of the Array BioPharma Inc. AcquisitionAnnounces Reverse Morris Trust... More